Navigation Links
Allon Therapeutics to Present New Data at Leerink Swann Alzheimer's,Conference

VANCOUVER, British Columbia--(BUSINESS WIRE)--Apr 3, 2007 - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection Company(TM), announced today the publication of new preclinical data from additional confirmatory animal studies showing that Allon's product candidate AL-108 significantly reduces the accumulation of amyloid peptide and the hyperphosphorylation of tau protein in the brain, two pathological hallmarks of Alzheimer's.

Gordon McCauley, Allon's President and Chief Executive Officer, announced this publication to a conference in New York sponsored by investment bank Leerink Swann & Company entitled "A Mind is a Terrible Thing to Waste: Emerging Trends for Alzheimer's Disease." The invitation only event for institutional investors, venture capitalists and hedge fund managers who invest in the healthcare sector, highlights select companies developing Alzheimer's treatments.

"Our Alzheimer's program is based on this very compelling data showing that our compounds work on both of the classic hallmarks of Alzheimer's disease and the Phase II efficacy program is enrolling well," said McCauley. "We believe that we have implemented a sound and strategically balanced clinical plan for our compounds and we anticipate the results eagerly."

"Data published in The Journal of Molecular Neuroscience shows that AL-108 can modify disease progression in one of the most relevant models of Alzheimer's disease and our clinical development program is working to demonstrate this capability in human clinical trials," McCauley said.

McCauley said Allon is focused on developing drugs to treat processes underlying numerous neurodegenerative diseases and injury of the central nervous system. Drugs on the market today treat only the symptoms of these diseases and conditions.

Webcast and Conference location

Allon Therapeutics' presentation will take place on Tuesday, April 3, 2007 at 2:15pm Ea
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:5/22/2013)... STEPh, Inc., a full service medical communications ... web site ( http://www.stephreports.com ) dedicated to ... STEPh Reports STEPh Reports are comprehensive critical ... STEPh Report assesses the competitive landscape by individual drug ... and specific key issues.  STEPh Reports are written by ...
(Date:5/22/2013)... Minn. , May 22, 2013 /PRNewswire/ ... the successful completion of its global Phase ... an internally developed program for the management ... proprietary formulation technology.  USL255 is specifically engineered ... fluctuations in topiramate blood levels observed with ...
(Date:5/22/2013)... 2013 MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) would ... some recent company developments. As Medifirst continues to expand ... with shareholders. Integrating social media into its investor relations ... will post updates on Twitter.  The Facebook homepage is ... Says CEO Bruce J. Schoengood ...
Breaking Medicine Technology:Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site 2Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 2Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 3Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 4Medifirst Solutions, Inc. Announces Update To Shareholders 2
... 60,000 young children end up in emergency rooms every ... caregivers were not looking. To remind parents and caregivers ... for Disease Control and Prevention (CDC) and the Consumer ... the PROTECT Initiative , today launched the ...
... Dec. 13 , 2011 Mirixa Corporation, the leader ... that Stacey Lelko has joined the company as Vice ... lead Mirixa,s national sales team and develop strategic partner ... Ms. Lelko most recently served as Vice President ...
Cached Medicine Technology:CDC and CHPA Educational Foundation Launch Up and Away and Out of Sight 2CDC and CHPA Educational Foundation Launch Up and Away and Out of Sight 3Mirixa Names New VP of Sales and Business Development 2
(Date:5/22/2013)... By Amy Norton HealthDay Reporter , , WEDNESDAY, ... wrestled with athlete,s foot knows there is something about ... have the first detailed "map" of the fungal groups ... feet are the hottest neighborhood. It,s no ... organisms, such as bacteria, viruses and fungi, both outside ...
(Date:5/22/2013)... May 22, 2013 Successful Therapy ... Patricia O’Laughlin Psychotherapy in the Silver Lake community ... all ages as progression to existing Parents and ... ages into parenting therapy has always been suggested, ... O’Laughlin Psychotherapy now specializes in all aspects of ...
(Date:5/22/2013)... According to a May 14, 2013 US News ... Breast Cancer Surgery,” modern medical technology has given women with ... in a whole new light. Since the new approach known ... breast cancer and mastectomies with greater hope for a ... of plastic surgery to oncology, women had little choice but ...
(Date:5/22/2013)... disparities from the University of Miami Miller School of ... teamed up to hold the second annual "Why We ... Medicine." The theme of this year,s conference will ... reduce these disparities. , Despite steady improvement in the ... groups continue to be more vulnerable to lapses in ...
(Date:5/22/2013)... Award Presented at the 2013 Annual ... here: http://bit.ly/13DkFfk , Merrill Corporation is pleased ... Product/Service of the Year” at the 7th M&A Advisor ... Hotel in Palm Beach, Florida. , Merrill DataSite ... solution that optimizes the due diligence process and ...
Breaking Medicine News(10 mins):Health News:Scientists Map the Fungi on Your Feet 2Health News:Scientists Map the Fungi on Your Feet 3Health News:Patricia O’Laughlin Psychotherapy of Los Angeles Now Seeing Adults, Teens and Young Children 2Health News:Breast Augmentation – New Option for Breast Cancer Surgeries 2Health News:Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 3
... submitted by Age Concern and London School of Hygiene and ... years are having an increased threat for disease due to ... that old age people are not spending the required amount ... eye care costs and are not undergoing the recommended 30 ...
... and doctors, and increases medical error risks, according to ... heating and cooling systems and by loud voices of ... short-term memory, according to the study by Johns Hopkins ... two-year research project, acoustics experts Ilene Busch-Vishniac and James ...
... that more lizard families than assumed till now are ... , The researchers, writing in the journal Nature ... like pain and swelling from lizard bites, which were ... of meat left between their teeth from their scavenging ...
... diabetes as a strong risk factor for sudden cardiac ... the disease.// ,The authors writing in the October ... prevalence of diabetes mellitus in industrialized countries is rapidly ... high risk for sudden cardiac death. ,The ...
... organisms, are exposed to ever-changing environments, oxidative stress, ... to defend themselves against all these insults, gain ... simply by ‘stealing’ genetic information from other better-adapted ... sex, known as horizontal gene transfer. ...
... A dengue fever vaccine full of promise is being tried ... of the GlaxoSmithKline vaccine //have been completed in the US ... be finished by the end of next year, Dr. Hans ... strong interest in making the vaccine available fast, given that ...
Cached Medicine News:Health News:More Lizards, Including Pets, Found Venomous 2Health News:Bacteria Evolve Armamentarium Against Antibiotics By ‘Stealing’ Gen 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: